Alterations in the tumor suppressor gene p53 lead to impaired cell cycle control, allowing for the development and growth of tumors. To restore a loss of p53 function, we performed a phase I study of intratumoral gene therapy with adenovirus expressing wild-type p53 in patients with non-small cell lung cancer carrying mutations in the p53 gene. Furthermore, in a phase II study, gene therapy was complemented with simultaneous cisplatin/vinorelbine treatment. Biopsies were obtained from all treated patients before and 24 -48 hours after gene therapy to study changes in the expression of p53 target genes. We report here that in most of the cases, the target gene p21 was up-regulated, especially when injection of higher doses of p53-expressing adenovirus was combined with simultaneous chemotherapy, whereas Pig3, previously reported to be highly up-regulated by p53, generally did not show a clear increase. Interestingly, a clear p21 gene response was observed only in tumors showing stabilization or regression. We conclude that p21 appears to be up-regulated after adenovirus-mediated p53 gene transfer and is the most sensitive marker tested for biological response to gene therapy in the small cohort of non-small cell lung cancers that were studied.
M utation of the tumor suppressor gene p53 is the most frequent genetic alteration observed in human cancer. The p53 protein mediates cell cycle arrest and apoptosis in response to chemical-or radiationinduced DNA damage by modulating the expression of the target genes involved in these processes. Indeed, absence of functional p53 leads to defects in these pathways such that subsequent cell growth arrest and death are impaired, further allowing development and growth of tumors. 1 Moreover, it has been shown that tumors carrying p53 mutations are resistant to treatment with radiation and chemotherapy, 2 and that restoration of the wild-type (wt) p53 function can lead to a reduction of tumor expansion 3 and can render tumors sensitive to radiation or cytostatic compounds. 4 Taken together, these data suggest the possibility of transferring the wt p53 gene into tumors of patients with a loss of p53 normal function.
Using a retrovirus-mediated approach, Roth et al 5 have shown that apoptosis was more frequently observed in biopsies taken after rather than before treatment, followed, in some cases, by tumor stabilization or regression. Moreover, one might expect that p53 gene therapy would render targeted tumor cells capable of responding to chemotherapy by triggering p53-mediated cell growth arrest and apoptosis pathways. 5 To that end, we have performed gene therapy by introduction of an adenovirus genetically engineered to express wt p53 (rAd-p53) on eligible patients in a phase I clinical trial; in addition, a phase II trial was initiated in which patients received this therapy in association with complementary chemotherapy. A report on the clinical outcome of these patients (phase I) has already been published. 6 To monitor the efficacy of gene transfer, biopsies were obtained from treated patients to study the p53 transgene 6 and p53 target gene expression.
MATERIALS AND METHODS

In vitro adenovirus infection
The p53-deficient ovary adenocarcinoma cell line 2774 (CRL-10303; American Type Culture Collection, Manassas, Va) was treated with 10 10 particles/mL of rAd-p53 or with control adenovirus not expressing p53. The medium was removed after 1 hour, and cells were supplemented with fresh medium. RNA was extracted at 1, 8, and 24 hours postinfection, reversetranscribed, and subjected to quantitative real-time polymerase chain reaction (PCR) (TaqMan on a Applied Biosystems Prism 7700 sequence detector; Perkin-Elmer/Applied Biosystems, Foster City, Calif).
Gene therapy trials
Patient enrollment, including positivity of intratumoral (i.t.) p53 protein accumulation by immunohistochemical detection, has been described previously by Schuler et al. 6 Among patients treated in multicenter phase I and II trials, only those treated in Basel (patients 1-5 for the phase I trial and patients 6 -9 for the phase II trial) were subjected to this pilot study. Phase I consisted of a dose escalation of one single injection by bronchoscopy of rAd-p53 (10 7 to 10 10 plaque-forming units (pfu)) according to protocols detailed in Schuler et al. 6 Phase II consisted of an injection of rAd-p53 (10 10 pfu) on day 1 of each of three 4-week cycles of a cisplatin (100 mg/m 2 ; day 1) and vinorelbine (25 mg/m 2 ; days 1, 8, 15, and 22) regimen (Table 1) . In both studies, follow-up was performed 28 days after rAd-p53 introduction (manuscript of phase I study in preparation).
Biopsy isolation and RNA expression analysis
Bronchial biopsies were isolated before and 24 hours after each rAd-p53 i.t. injection (48 hours in patients 1 and 2), and RNA from these biopsies was purified and reverse-transcribed. cDNA derived from the same biopsies was used (a) to assess transgene expression by semiquantitative PCR with primers specific for vector-expressed p53, as described in Schuler et al, 6 and (b) for quantitative real-time PCR to determine p53 target gene expression.
Quantitative real-time PCR
Quantitative real-time PCR was performed using TaqMan on a Applied Biosystems Prism 7700 sequence detector. Reactions were done in triplicate and theoretical threshold cycle (Ct) values were calculated by the built-in software. RNA amounts were standardized by subtracting the Ct values obtained for p21 and Pig3 target genes from that of the reference gene 36B4 on the same sample (⌬Ctp21 and ⌬CtPig3). Relative expression profiles were obtained by subtraction of ⌬Ct values at time 0 (t0) from those after gene transfer (⌬Ctp21-⌬Ctp21t0 and ⌬CtPig3-⌬CtPig3t0); final quantitation was calculated as 2E(⌬Ctp21-⌬Ctp21t0) and 2E(⌬CtPig3-⌬CtPig3t0). Primers and probes were designed using Primer Express software (Perkin-Elmer Applied Biosystems). The following primers were used: AGCAAGTGGGAAGGTGTAATCC and CCATTCTATCATCAACGGGTACAA (36B4), CTG-GAGACTCTCAGGGTCGAA and CCGGCGTTTGGAGT-GGTA (p21), TTAATGCAGAGACAAGGCCAGTAT and CAGATGCCTCAAGTCCCAAAA (Pig3). In addition, the following probes were used: TCTCCACAGACAAGGCCAG-GACTCG (36B4), ACGGCGGCAGACCAGCATGAC (p21), and ACCCACCTCCAGGAGCCAGCAAC (Pig3).
RESULTS
In a preliminary experiment, we wanted to study changes in the expression of the p53 target genes p21 and Pig3 during the process of in vitro p53 rescue. To do so, the p53-deficient ovary adenocarcinoma cell line 2774 was infected with rAd-p53, and cells were harvested at 1, 8, and 24 hours postinfection for RNA extraction and subsequent quantitative PCR. As a reference gene, we used 36B4, previously identified for its constitutive expression in breast cancer cell lines. 7 Compared with noninfected cells, both genes, especially p21, showed a dramatic increase in expression detected as early as 8 hours postinfection. Indeed, the highest values obtained for p21 and Pig3 reach a 500-fold and a 50-fold increase at 24 hours postinfection, respectively (Fig 1, left portion) . In comparison, a simultaneous infection per- formed with a control adenoviral vector that does not encode p53 showed no increase in the expression of either gene (Fig 1, right portion) , confirming that upregulation of either p53 target gene is not the result of adenoviral infection. Patient assessments in the phase I study indicated that transient local disease control was observed in the tumors for which the presence of the transgene was detected, with no evidence of clinical responses at untreated tumor sites and of toxicity of the adenoviral vector. 6 RNA extracted from biopsies isolated before and after introduction of rAd-p53 was reverse-transcribed and subject to quantitative real-time PCR for the expression of two genes known to be highly up-regulated by p53: the p21 gene, a direct target of the transcription factor p53 8 and involved in cell cycle control, 9 and Pig3, a gene that is dramatically up-regulated in the colorectal cell line SW480 after infection with an adenovirus expressing wt p53. 10 In phase I, relative to the 36B4 gene expression, RNA samples from these patients showed diverse responses of both p53 target genes. Indeed, p21 gene expression was significantly increased in two cases: patients 2 (18.4-fold) and 3 (3.5-fold), precisely the ones that have previously shown positivity for p53 transgene expression in the same biopsy samples 6 and local stabilization of the injected tumor. However, Pig3 showed one significant peak (3.2-fold) in patient 1 (Fig 2) , indicating that both p53 target genes are not tightly coregulated.
A subsequent phase II study was performed using three cycles of i.t. p53 gene transfer in patients at the highest dose of rAd-p53 given during phase I, together with additive cisplatin/vinorelbine chemotherapy ( Table  1 ). In all phase II patients, p21 gene levels were increased at least 3-fold and up to 22-fold in almost all the treatment cycles. Again, Pig3 RNA levels significantly increased in only patient 9 (3.1-to 5.5-fold) during cycles 1 and 2 (Fig 2) , indicating that, like in the previous study, p21 and Pig3 do not appear to be tightly coregulated by p53. However, p21 expression profiles demonstrate a response to rAd-p53 treatment that might further lead to local stabilization or remission of the injected tumor. Thus, these results suggest the possibility of restoring p53-mediated cell cycle arrest and apoptosis after combined treatment with gene therapy and chemotherapy.
DISCUSSION
To monitor the efficacy of adenovirus-mediated p53 therapy, we selected two target genes, p21 and Pig3, based on the fact that they are highly up-regulated by p53. 9, 10 Our data demonstrate that in patients treated with simultaneous gene therapy and chemotherapy, p21 shows a clear up-regulation. However, the p21 response measured from biopsies is not as strong as that observed in our preliminary in vitro study. This difference can be explained by the fact that the tumor is formed of a heterogeneous population of cells that are more or less permissive to adenovirus infection, and that tumor biopsies may contain up to 50% of normal tissue, mostly blood vessels and blood cells. In addition, a possible lack of accuracy of the biopsy extraction compared with the site of injection might also play a role. Conversely, the 2774 cell line appears to be highly sensitive to adenoviral infection. The marked increase in p21 responses in phase II compared with phase I is either due to higher doses of injected rAd-p53 or to the effect of the simultaneous chemotherapeutic treatment. However, we obtained no evidence for p21 up-regulation by cisplatin treatment in vitro on tumor models (our unpublished observations), suggesting that the stronger p21 response is due instead to the higher dose of injected rAd-p53 in the phase II study. Surprisingly, Pig3 does not appear to be as tightly coregulated in vivo with the p21 gene as expected. p21 blocks cell progression by inhibiting the phosphorylation of the cyclin-dependent kinase Cdk2, 9 whereas Pig3 encodes an homolog of quinone oxidoreductase. 10 Therefore, the possible involvement of Pig3 in the cell cycle regulatory process remains unclear. In addition, other p53 target genes that we analyzed, such as mdm2, bax, bcl2, and Pig12, did not show clear response patterns (data not shown).
Overexpression of wt p53 has been shown previously to induce p21 transcription within 24 -48 hours. 11 It is noteworthy that in phase I, samples from patients 2 and 3, who had the strongest increase in p21 gene expression, were shown previously to contain the p53 transgene by an independent PCR on cDNA from the same biopsy 6 (see also Table 1 ). Moreover, at the follow-up at 28 days posttreatment, both patients showed stabilization of the injected tumor, as opposed to patients 1, 4, and 5, who were negative for both p53 transgene expression and p21 increase and had rapidly progressing tumors. Taken together, the observations from phase I suggest that tumor stabilization might be a consequence of the efficiency of p53 wt gene transfer. When p53 gene transfer was complemented with chemotherapy, injected tumors showed local stabilization in two patients and partial remission and even complete remission of the local lesion in one patient each. Interestingly, the two patients who responded the best also showed a substantial p21 gene up-regulation after all three cycles of treatment, as opposed to the two patients with stabilization. However, the number of samples was too low for a meaningful statistical analysis to corroborate these findings. Nevertheless, among the studied p53 target genes, p21 seemed the most reliable one, not only to monitor tumor injection efficiency, but also to attest to transgene activity. In addition, together with the data from longterm follow-up of injected tumors, these results suggest that restoration of the p53 pathway leads to sensitization of tumor cells to chemotherapy.
In conclusion, we have shown that expression of the p53 target gene p21 was significantly increased after rAd-p53-mediated gene therapy, indicating efficiency of the rAd-p53 delivery process and functionality of the transgene product, and therefore suggesting evidence for the restoration of subsequent p53-mediated cell cycle arrest/apoptosis in injected tumors. Table 1 . prog, progressive; stab, stable; c rem, complete remission; p rem, partial remission.
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